Trial · NCT02549937
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose-Escalation Phase: Surufatinib 50 Milligrams (mg) | 3 | |
| Overall Study | STARTED | Dose-Escalation Phase: Surufatinib 100 mg | 7 | |
| Overall Study | STARTED | Dose-Escalation Phase: Surufatinib 200 mg | 3 | |
| Overall Study | STARTED | Dose-Escalation Phase: Surufatinib 300 mg | 9 | |
| Overall Study | STARTED | Dose-Escalation Phase: Surufatinib 400 mg | 13 | |
| Overall Study | STARTED | Dose-Expansion Phase: Arm A: BTC | 30 | |
| Overall Study | STARTED | Dose-Expansion Phase: Arm B: pNET | 16 | |
| Overall Study | STARTED | Dose-Expansion Phase: Arm C: epNET | 16 | |
| Overall Study | STARTED | Dose-Expansion Phase: Arm D: STS | 33 | |
| Overall Study | COMPLETED | Dose-Escalation Phase: Surufatinib 50 Milligrams (mg) | 0 | |
| Overall Study | COMPLETED | Dose-Escalation Phase: Surufatinib 100 mg | 0 | |
| Overall Study | COMPLETED | Dose-Escalation Phase: Surufatinib 200 mg | 0 | |
| Overall Study | COMPLETED | Dose-Escalation Phase: Surufatinib 300 mg | 0 | |
| Overall Study | COMPLETED | Dose-Escalation Phase: Surufatinib 400 mg | 0 | |
| Overall Study | COMPLETED | Dose-Expansion Phase: Arm A: BTC | 0 | |
| Overall Study | COMPLETED | Dose-Expansion Phase: Arm B: pNET | 0 | |
| Overall Study | COMPLETED | Dose-Expansion Phase: Arm C: epNET | 0 | |
| Overall Study | COMPLETED | Dose-Expansion Phase: Arm D: STS | 0 | |
| Overall Study | NOT COMPLETED | Dose-Escalation Phase: Surufatinib 50 Milligrams (mg) | 3 | |
| Overall Study | NOT COMPLETED | Dose-Escalation Phase: Surufatinib 100 mg | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02549937/flow